Alnylam Pharmaceuticals, Inc. (ALNY) Stock Forecast
Data as of Jun 16, 2026Healthcare · Current price $281.92 (-2.10%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 12, 2026 | Paul Matteis | Stifel Nicolaus | $444.00 | +57.5% |
| Jan 12, 2026 | Martin Auster | Raymond James | $472.00 | +67.4% |
| Dec 15, 2025 | Mani Foroohar | Leerink Partners | $351.00 | +24.5% |
| Nov 4, 2025 | Patrick Trucchio | H.C. Wainwright | $570.00 | +102.2% |
| Oct 31, 2025 | Leland Gershell | Oppenheimer | $500.00 | +77.4% |
| Oct 31, 2025 | Keay Nakae | Chardan Capital | $475.00 | +68.5% |
| Oct 30, 2025 | Michael Ulz | Morgan Stanley | $495.00 | +75.6% |
| Oct 6, 2025 | Michael Ulz | Morgan Stanley | $475.00 | +68.5% |
| Oct 6, 2025 | Paul Matteis | Stifel Nicolaus | $495.00 | +75.6% |
| Sep 5, 2025 | Kostas Biliouris | BMO Capital | $470.00 | +66.7% |
| Jul 21, 2025 | Danielle Brill | Truist Financial | $385.00 | +36.6% |
| Jun 24, 2025 | Kostas Biliouris | BMO Capital | $360.00 | +27.7% |
| Jan 7, 2025 | William Pickering | Bernstein | $310.00 | +10.0% |
| Oct 24, 2024 | Whitney Ijem | Canaccord Genuity | $336.00 | +19.2% |
| Oct 1, 2024 | Whitney Ijem | Canaccord Genuity | $366.00 | +29.8% |
| Sep 27, 2024 | Tazeen Ahmad | Bank of America Securities | $307.00 | +8.9% |
| Aug 27, 2024 | Kostas Biliouris | BMO Capital | $300.00 | +6.4% |
| Aug 26, 2024 | Luca Issi | RBC Capital | $300.00 | +6.4% |
| Aug 16, 2024 | Salveen Richter | Goldman Sachs | $370.00 | +31.2% |
| Jul 8, 2024 | Whitney Ijem | Canaccord Genuity | $357.00 | +26.6% |
Top Analysts Covering ALNY
ALNY vs Sector & Market
| Metric | ALNY | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.18 | 2.24 | 2.40 |
| Analyst Count | 22 | 8 | 19 |
| Target Upside | +57.3% | +11475.0% | +17.1% |
| P/E Ratio | 66.96 | 3.85 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $1.25B | $1.32B | $1.42B | 13 |
| 2026-09-30 | $1.37B | $1.48B | $1.59B | 6 |
| 2026-12-31 | $1.54B | $1.66B | $1.78B | 6 |
| 2027-03-31 | $1.71B | $1.84B | $1.98B | 6 |
| 2027-06-30 | $1.81B | $1.95B | $2.10B | 6 |
| 2027-09-30 | $1.92B | $2.06B | $2.22B | 6 |
| 2027-12-31 | $2.04B | $2.19B | $2.36B | 6 |
| 2028-12-31 | $8.74B | $8.77B | $8.80B | 19 |
| 2029-12-31 | $9.19B | $9.99B | $11.74B | 10 |
| 2030-12-31 | $10.45B | $11.35B | $13.34B | 16 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $1.16 | $1.49 | $1.87 | 8 |
| 2026-09-30 | $1.72 | $1.89 | $2.08 | 3 |
| 2026-12-31 | $2.12 | $2.33 | $2.56 | 6 |
| 2027-03-31 | $2.49 | $2.74 | $3.02 | 3 |
| 2027-06-30 | $2.49 | $2.74 | $3.01 | 5 |
| 2027-09-30 | $2.81 | $3.09 | $3.40 | 3 |
| 2027-12-31 | $3.02 | $3.32 | $3.66 | 6 |
| 2028-12-31 | $9.60 | $13.07 | $20.01 | 17 |
| 2029-12-31 | $14.32 | $15.98 | $19.62 | 13 |
| 2030-12-31 | $17.10 | $19.08 | $23.43 | 7 |
Frequently Asked Questions
What is the analyst consensus for ALNY?
The consensus among 22 analysts covering Alnylam Pharmaceuticals, Inc. (ALNY) is Buy with an average price target of $460.50.
What is the highest price target for ALNY?
The highest price target for ALNY is $570.00, set by Patrick Trucchio at H.C. Wainwright on 2025-11-04.
What is the lowest price target for ALNY?
The lowest price target for ALNY is $154.00, set by Zhiqiang Shu at Berenberg Bank on 2022-02-11.
How many analysts cover ALNY?
22 analysts have issued ratings for Alnylam Pharmaceuticals, Inc. in the past 12 months.
Is ALNY a buy or sell right now?
Based on 22 analyst ratings, ALNY has a consensus rating of Buy (2.18/5) with a +57.3% upside to the consensus target of $460.50.
What are the earnings estimates for ALNY?
Analysts estimate ALNY will report EPS of $1.49 for the period ending 2026-06-30, with revenue estimated at $1.32B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.